UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

British journal of dermatology (1951), 2015-02, Vol.172 (2), p.484-493

2015

Volltextzugriff (PDF)

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

British journal of dermatology (1951), 2015-05, Vol.172 (5), p.1395-1406

2015

Volltextzugriff (PDF)

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

British journal of dermatology (1951), 2019-10, Vol.181 (4), p.733-742

2019

Volltextzugriff (PDF)

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials

Journal of the European Academy of Dermatology and Venereology, 2019-12, Vol.33 (12), p.2305-2312

2019

Volltextzugriff (PDF)

Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema

Journal of the European Academy of Dermatology and Venereology, 2017-06, Vol.31 (6), p.1056-1063

2017

Volltextzugriff (PDF)

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

Journal of the European Academy of Dermatology and Venereology, 2013-12, Vol.27 (12), p.1535-1545

2013

Volltextzugriff (PDF)

Rapid improvements in health‐related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER‐2 and UNCOVER‐3

Journal of the European Academy of Dermatology and Venereology, 2017-09, Vol.31 (9), p.1483-1490

2017

Volltextzugriff (PDF)

Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1

British journal of dermatology (1951), 2014-02, Vol.170 (2), p.398-407

2014

Volltextzugriff (PDF)

Three‐year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial

Journal of the European Academy of Dermatology and Venereology, 2021-12, Vol.35 (12), p.2398-2408

2021

Volltextzugriff (PDF)

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

Journal of the European Academy of Dermatology and Venereology, 2017-06, Vol.31 (6), p.1004-1013

2017

Volltextzugriff (PDF)

Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study

British journal of dermatology (1951), 2021-10, Vol.185 (4), p.840-842

2021

Volltextzugriff (PDF)

Noninvasive genomic detection of melanoma

British journal of dermatology (1951), 2011-04, Vol.164 (4), p.797-806

2011

Volltextzugriff (PDF)

Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials

Journal of the European Academy of Dermatology and Venereology, 2011-07, Vol.25 (7), p.851-857

2011

Volltextzugriff (PDF)

Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase III trials

Journal of the European Academy of Dermatology and Venereology, 2018-01, Vol.32 (1), p.68-72

2018

Volltextzugriff (PDF)

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study

Journal of the European Academy of Dermatology and Venereology, 2017-10, Vol.31 (10), p.1693-1699

2017

Volltextzugriff (PDF)

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, 2017-02, Vol.31 (2), p.323-332

2017

Volltextzugriff (PDF)

ASN002 证明有疗效并可改善AD 炎症

British journal of dermatology (1951), 2019-10, Vol.181 (4), p.e113-e113

2019

Volltextzugriff (PDF)

ASN002 demonstrates efficacy and improves inflammation in AD

British journal of dermatology (1951), 2019-10, Vol.181 (4), p.e102-e102

2019

Volltextzugriff (PDF)

A reliability study using Network Oriented Research Assistant (NORA®) examining the use of digital photographs in the assessment of psoriasis

British journal of dermatology (1951), 2019-07, Vol.181 (1), p.214-215

2019

Volltextzugriff (PDF)

Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: Letter to the Editor

Journal of the European Academy of Dermatology and Venereology, 2019-10, Vol.33 (10), p.e350-e352

2019

Volltextzugriff (PDF)

Impact of ixekizumab treatment on skin‐related personal relationship difficulties in moderate‐to‐severe psoriasis patients: 12‐week results from two Phase 3 trials

Journal of the European Academy of Dermatology and Venereology, 2017-11, Vol.31 (11), p.1867-1875

2017

Volltextzugriff (PDF)

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

The Lancet (British edition), 2012-08, Vol.380 (9843), p.738-746

2012

Volltextzugriff (PDF)

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Annals of the rheumatic diseases, 2014-06, Vol.73 (6), p.990-999

2014

Volltextzugriff (PDF)

Perspectives on Living with Chronic Spontaneous Urticaria: From Onset through Diagnosis and Disease Management in the US

Acta dermato-venereologica, 2019-11, Vol.99 (12), p.1091-1098

2019

Volltextzugriff (PDF)

POS1046 DEUCRAVACITINIB LONG-TERM EFFICACY AND SAFETY IN PLAQUE PSORIASIS: 2-YEAR RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.841-841

2022

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(65)

Publikationsform

Sprache

Englisch
(67)
Französisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(43)
Life Sciences & Biomedicine
(40)
Humans
(35)
Dermatology
(30)
Male
(27)
Middle Aged
(26)
Adult
(25)
Female
(25)
Double-Blind Method
(18)
Psoriasis - Drug Therapy
(17)
Treatment Outcome
(16)
Severity Of Illness Index
(13)
Psoriasis
(12)
Aged
(11)
Quality Of Life
(10)
Original
(9)
Antibodies, Monoclonal - Therapeutic Use
(7)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(7)
Clinical Trials
(7)
General & Internal Medicine
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials

Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

Rapid improvements in health‐related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER‐2 and UNCOVER‐3

Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1

Three‐year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study

Noninvasive genomic detection of melanoma

Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials

Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase III trials

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

ASN002 证明有疗效并可改善AD 炎症

ASN002 demonstrates efficacy and improves inflammation in AD

A reliability study using Network Oriented Research Assistant (NORA®) examining the use of digital photographs in the assessment of psoriasis

Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: Letter to the Editor

Impact of ixekizumab treatment on skin‐related personal relationship difficulties in moderate‐to‐severe psoriasis patients: 12‐week results from two Phase 3 trials

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

Perspectives on Living with Chronic Spontaneous Urticaria: From Onset through Diagnosis and Disease Management in the US

POS1046 DEUCRAVACITINIB LONG-TERM EFFICACY AND SAFETY IN PLAQUE PSORIASIS: 2-YEAR RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM

Suchergebnisse filtern